Saturday 17 October 2026 Export SYK’s income statement to Excel — free account

Stryker Corporation

Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.

294.66 1.43 +0.49%

Follow SYK

Alert me

Market cap: $112.5B
P/E: 30.3×
Fwd P/E: 24.1×
Dividend yield: 1.19%
F-score: 5/9
Altman Z: 4.81
Beneish M: −2.62
Dividend safety: 82/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Officer departure Oct 6, 2026

All filings →

Insider Decisions trades per month

Total sells 586.13

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	—	—	2	—	—	3	—	—	3	—	—

Insider Ownership 5.87%

Capital & Financial Ratios $m

Market Cap 112,480.00

Revenue 25,837.00

Net Income 3,729.00

Free Cash Flow 4,702.00

Net Debt 11,466.00

Current Ratio 2.16

Debt/Equity 0.62

P/E ratio 30.28

Fwd P/E 24.10

P/S ratio 4.37

P/B ratio 4.71

Past 5Y EPS Growth 14.87%

This Y EPS Growth 9.73%

Next Y EPS Growth 11.56%

Next Y revenue growth 8.32%

Next 5Y EPS Growth 10.90%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 24.11%

10-year low 10-year high

P/S against its own 10 years 16.29%

10-year low 10-year high

P/B against its own 10 years 7.67%

10-year low 10-year high

EV/Sales against its own 10 years 17.47%

10-year low 10-year high

EV/FCF against its own 10 years 3.46%

10-year low 10-year high

Dividends

Payout Ratio 0.36

Annual Dividend Rate 3.52

Annual Dividend Yield 1.19%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	3.59	0.88 0.88 0.88
2025	3.40	0.84 0.84 0.84 0.88
2024	3.24	0.80 0.80 0.80 0.84
2023	3.05	0.75 0.75 0.75 0.80
2022	2.84	0.70 0.70 0.70 0.75
2021	2.59	0.63 0.63 0.63 0.70
2020	2.36	0.58 0.58 0.58 0.63
2019	2.14	0.52 0.52 0.52 0.58
2018	1.93	0.47 0.47 0.47 0.52
2017	1.75	0.43 0.43 0.43 0.47
2016	1.57	0.38 0.38 0.38 0.43

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3,053	4,493	4,100	3,476
Receivables	3,765	3,987	4,039	3,743
Inventory	4,843	4,774	5,310	5,521
Other	—	—	—	—
	12,518	14,847	14,755	14,418

	2023	2024	2025	Q'26
Payables	1,517	1,679	1,799	1,663
ST’ Debt	2,094	1,409	1,000	750
Other	—	—	—	—
	7,921	7,616	7,794	6,684

Compound Annual Growth %

	10y	5y	3y
Sales	9.71%	11.84%	10.83%
Cash Flow	17.79%	9.01%	24.34%
Earnings	8.47%	15.21%	11.24%
Book Value	10.17%	11.37%	10.50%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6,020	6,589	—	—	—
’25	5,866	6,022	6,057	7,171	25,116
’24	5,243	5,422	5,494	6,436	22,595
’23	4,778	4,996	4,909	5,815	20,498
’22	4,275	4,493	4,479	5,202	18,449
’21	3,953	4,294	4,160	4,701	17,108
’20	3,588	2,764	3,737	4,262	14,351

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	581	1,261	—	—	—
’25	250	1,111	1,540	2,143	5,044
’24	204	633	1,474	1,931	4,242
’23	445	688	1,050	1,528	3,711
’22	203	529	889	1,003	2,624
’21	452	878	933	1,000	3,263
’20	591	620	829	1,237	3,277

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	415	1,059	—	—	—
’25	127	928	1,518	1,710	4,283
’24	37	481	1,304	1,665	3,487
’23	315	536	902	1,383	3,136
’22	84	386	751	815	2,036
’21	369	772	803	794	2,738
’20	447	511	760	1,072	2,790

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.93	3.30	—	—	—
’25	1.69	2.29	2.22	2.20	8.40
’24	2.05	2.14	2.16	1.41	7.76
’23	1.54	1.93	1.80	2.98	8.25
’22	0.84	1.72	2.14	1.47	6.17
’21	0.79	1.55	1.14	1.73	5.21
’20	1.30	(0.22)	1.63	1.49	4.20

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	86.68	116.50	144.75	151.63	124.54	220.90	188.84	243.79	292.43	329.16	Analyst estimates 2026–2028 Powerpack
	High	123.55	160.62	179.84	223.45	245.34	281.16	280.43	306.93	398.20	406.19
People
People	Employees	33,000	33,000	36,000	40,000	43,000	46,000	51,000	52,000	53,000	56,000
	Revenue/emp, $m	0.34	0.38	0.38	0.37	0.33	0.37	0.36	0.39	0.43	0.45
Income, $m
Income, $m	Revenue	11,325	12,444	13,601	14,884	14,351	17,108	18,449	20,498	22,595	25,116
	Gross margin, %	66.26	65.73	65.72	65.14	63.11	64.11	62.76	63.70	63.91	63.96
	EBT	1,921	2,063	2,356	2,562	1,954	2,281	2,683	3,673	3,492	4,514
	EBT margin, %	16.96	16.58	17.32	17.21	13.62	13.33	14.54	17.92	15.45	17.97
	Net income	1,647	1,020	3,553	2,083	1,599	1,994	2,358	3,165	2,993	3,246
	Depreciation	546	642	723	778	812	990	998	1,028	1,050	1,193
Per share, $
Per share, $	Revenue	30.27	33.27	36.36	39.80	38.22	45.38	48.78	54.00	59.30	65.71
	Earnings	4.40	2.73	9.50	5.57	4.26	5.29	6.23	8.34	7.86	8.49
	Cash flow	5.12	4.17	6.98	5.86	8.73	8.66	6.94	9.78	11.13	13.20
	Capex	(1.31)	(1.60)	(1.53)	(1.74)	(1.30)	(1.39)	(1.55)	(1.51)	(1.98)	(1.99)
	Free cash flow	3.81	2.57	5.45	4.12	7.43	7.26	5.38	8.26	9.15	11.21
	Book value	25.53	26.68	31.36	34.24	34.84	39.46	43.93	48.98	54.16	58.66
	Shares, m	374	374	374	374	376	377	378	380	381	382
Valuation, ×
Valuation, ×	P/E	27.08	57.84	16.52	37.69	57.39	50.55	39.49	35.52	45.87	41.40
	P/S	3.95	4.75	4.31	5.28	6.41	5.89	5.04	5.49	6.07	5.35
	P/B	4.68	5.92	5.00	6.13	7.03	6.78	5.60	6.05	6.65	5.99
	EV/Sales	4.26	5.10	4.76	5.72	7.18	6.45	5.65	5.97	6.47	5.82
	EV/FCF	33.83	66.06	31.80	55.24	36.91	40.28	51.16	39.03	41.95	34.11
Cash, $m
Cash, $m	Operating cash flow	1,915	1,559	2,610	2,191	3,277	3,263	2,624	3,711	4,242	5,044
	Capex	(490)	(598)	(572)	(649)	(487)	(525)	(588)	(575)	(755)	(761)
	Free cash flow	1,425	961	2,038	1,542	2,790	2,738	2,036	3,136	3,487	4,283
Balance, $m
Balance, $m	Working capital	4,713	4,508	4,926	6,658	4,666	5,468	3,972	4,597	7,231	6,961
	Total debt	6,914	7,222	9,859	11,090	13,991	12,479	13,048	12,995	13,597	15,859
	Net debt	3,530	4,429	6,160	6,665	10,967	9,460	11,120	9,942	9,104	11,759
	Shareholders’ equity	9,550	9,980	11,730	12,807	13,084	14,877	16,616	18,593	20,634	22,420
Returns, %
Returns, %	ROA	8.99	4.79	14.38	7.26	4.96	5.78	6.59	8.24	7.22	7.15
	ROIC	10.39	9.96	8.86	8.71	5.78	6.64	6.40	8.52	7.75	8.94
	ROE	18.24	10.45	32.73	16.98	12.35	14.26	14.97	17.98	15.26	15.08

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABT Abbott Laboratories	$181.1B	33.9×	22.9×	+13.02% (above 0%: growing)	−47.52% (below 0%: shrinking)	+28.87% (above 0%: growing)	57.71%	13.44%	Compare
MDT Medtronic PLC	$122.1B	23.2×	18.7×	+13.73% (above 0%: growing)	+41.98% (above 0%: growing)	+120.89% (above 0%: growing)	64.99%	18.08%	Compare
SYK Stryker Corporation	$112.5B	30.3×	24.1×	+9.42% (above 0%: growing)	+43.10% (above 0%: growing)	+14.12% (above 0%: growing)	68.27%	25.18%
BSX Boston Scientific Corporation	$64.0B	17.9×	17.8×	+7.53% (above 0%: growing)	+14.81% (above 0%: growing)	+13.29% (above 0%: growing)	70.71%	21.65%	Compare
EW Edwards Lifesciences Corporation	$50.8B	49.8×	30.7×	+13.63% (above 0%: growing)	−26.32% (below 0%: shrinking)	+142.84% (above 0%: growing)	77.46%	29.48%	Compare
DXCM DexCom, Inc.	$33.1B	33.2×	29.8×	+13.08% (above 0%: growing)	+41.30% (above 0%: growing)	−11.68% (below 0%: shrinking)	63.44%	24.33%	Compare
GEHC GE HealthCare Technologies Inc.	$31.8B	16.0×	14.4×	+5.75% (above 0%: growing)	+16.98% (above 0%: growing)	+750.00% (above 0%: growing)	41.17%	13.96%	Compare
PHG Koninklijke Philips N.V.	$24.9B	18.8×	11.2×	+2.94% (above 0%: growing)	+56.67% (above 0%: growing)	+49.74% (above 0%: growing)	49.31%	13.99%	Compare
STE STERIS plc	$21.9B	27.1×	23.6×	+7.30% (above 0%: growing)	+13.89% (above 0%: growing)	−14.36% (below 0%: shrinking)	45.84%	19.15%	Compare
Median of peers	$41.9B	25.2×	20.8×	+10.28%	+15.90%	+39.31%	60.58%	18.61%

All 149 Medical Devices stocks →

Stryker Corporation (SYK) key facts

Strength: Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024.
Strength: Net income was $3.2 billion, or $8.49 per share (basic), a net margin of 12.9%.
Stryker Corporation (SYK) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, SYK traded at $294.66, a market capitalization of $112.5 billion.
At that price the stock trades at 30.3× trailing-twelve-month earnings and 4.4× sales; its P/E is higher than 24% of its own readings over the past ten years.
Stryker Corporation pays an annual dividend of $3.52 per share, a yield of 1.19%, with a payout ratio of 36.5%.
Return on equity was 15.1% and debt-to-equity 0.62.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.81 (safe zone) for fiscal 2025.